The global precision genomic testing market size is projected to rise from USD 15.57 Bn in 2024 to USD 62.34 Bn by 2034, expanding at a CAGR of 14.88%.
Precision Genomic Testing Market Key Takeaways
- North America dominated the market by holding more than 43% of market share in 2024.
- Asia Pacific is expected to grow at the fastest CAGR 20.63% over the forecast period.
- By product and services, the consumables segment held the biggest market share of 46% in 2024.
- By product and services, the services segment is projected to grow at a solid CAGR of 15.41% over the forecast period.
- By technology, the next-generation sequencing segment accounted for the major market share of 33% in 2024.
- By technology, the microarray technology segment is expanding at a notable CAGR of 15.80% during the projected period.
- By application, the oncology segment contributed the highest market share of 33% in 2024.
- By application, the neurological disorders segment is poised to grow at a double digit CAGR of 16% over the forecast period.
- By end use, the hospitals and clinics segment held the major market share of 51% in 2024.
- By end use, the diagnostic laboratories segment is projected to grow at the fastest rate during the forecast period.
Precision Genomic Testing Market Overview
The Precision Genomic Testing Market is experiencing robust growth due to the increasing emphasis on personalized medicine, advances in genomic technologies, and growing awareness of early disease detection and targeted treatment. Precision genomic testing analyzes an individual’s DNA to identify genetic variations that could contribute to disease development or influence therapeutic responses. This information helps clinicians design tailored treatment plans, ensuring higher efficacy and minimizing adverse effects. As the healthcare industry moves toward precision medicine, genomic testing is becoming an integral part of diagnostics and treatment planning, particularly in oncology, infectious diseases, cardiology, and rare genetic disorders.
The global precision genomic testing market was valued at approximately USD 10.25 billion in 2024 and is projected to reach around USD 24.37 billion by 2034, reflecting a compound annual growth rate (CAGR) of 9.2%. Factors such as increased investment in genomic research, greater adoption of next-generation sequencing (NGS), and improvements in bioinformatics and AI-driven genomic data analysis are driving market expansion. With the cost of genomic testing steadily decreasing and more applications emerging beyond oncology, the market is poised for significant growth over the next decade.
Precision Genomic Testing Market Drivers
The primary driver fueling the growth of the precision genomic testing market is the growing demand for personalized medicine, which tailors treatment plans to individual genetic profiles. Precision medicine enhances treatment outcomes by offering targeted therapies based on an individual’s genetic makeup, minimizing adverse effects and improving clinical outcomes. Another significant driver is the advancement in genomic technologies, including next-generation sequencing (NGS), whole genome sequencing, and CRISPR, which enable faster and more accurate genomic analysis. The continuous reduction in sequencing costs has made genomic testing more accessible to a wider population, contributing to increased adoption in clinical practice. Moreover, the growing prevalence of chronic and genetic diseases such as cancer, cardiovascular disorders, and rare genetic conditions has necessitated early and accurate diagnosis, thereby driving the adoption of precision genomic testing.
Government initiatives and funding for genomic research, such as the NIH’s All of Us Research Program and Genomics England’s initiatives, have also played a crucial role in boosting the market. Additionally, the rise in demand for companion diagnostics, which utilize genomic data to guide treatment decisions, further strengthens the growth trajectory of this market.
Precision Genomic Testing Market Opportunities
The precision genomic testing market presents several opportunities for growth and innovation. One notable opportunity lies in expanding genomic testing applications beyond oncology into areas such as infectious diseases, cardiology, and reproductive health. As the understanding of genomics deepens, new possibilities for precision diagnostics are emerging in various medical specialties. The integration of artificial intelligence (AI) in genomic analysis is another significant opportunity that enhances the speed and accuracy of data interpretation, enabling clinicians to make informed decisions faster.
AI-powered genomic platforms are revolutionizing clinical workflows and improving the efficiency of genomic analysis, presenting a lucrative growth avenue for market players. Emerging markets, particularly in Asia-Pacific and Latin America, also offer untapped potential for market expansion due to increasing healthcare infrastructure, rising awareness, and government initiatives promoting genomic research. Moreover, the growing number of pharmaceutical-biotech collaborations aimed at developing targeted therapies based on genomic insights opens new doors for innovation in precision medicine and diagnostics.
Market Challenges
Despite its promising growth, the precision genomic testing market faces several challenges. One of the most significant challenges is the high cost of genomic testing, which remains a barrier to widespread adoption, especially in developing countries. Although the cost of sequencing has decreased substantially, the overall expense of genomic testing, including interpretation and clinical application, can be prohibitive for many patients. Regulatory and ethical concerns regarding genomic data privacy and security also pose a challenge, as protecting sensitive genetic information remains a critical concern in the healthcare industry. Stringent regulatory frameworks and concerns related to the potential misuse of genetic data may slow down market growth.
Another challenge is the shortage of skilled professionals capable of interpreting complex genomic data, limiting the widespread implementation of genomic testing in clinical practice. Additionally, the limited awareness of genomic testing and its benefits among healthcare providers and patients further restricts the market’s growth potential.
Regional Insights
The precision genomic testing market exhibits diverse growth patterns across different regions. North America dominates the market, accounting for over 40% of the global revenue in 2024, driven by the presence of leading genomic research institutions, significant investments in genomic technologies, and favorable regulatory frameworks. The United States, in particular, leads the region due to its advanced healthcare infrastructure, government-funded research initiatives, and growing adoption of precision medicine. Europe holds a significant market share, driven by government initiatives such as Genomics England and increasing integration of genomic testing in routine clinical practice. Germany, France, and the UK are key contributors to market growth in the region.
Asia-Pacific is expected to witness the fastest growth, with a projected CAGR of over 11.5% during the forecast period. Countries like China, India, and Japan are investing heavily in genomic research and precision medicine, creating a conducive environment for market growth. Latin America is gradually adopting genomic technologies, with Brazil and Mexico emerging as key markets. The Middle East and Africa are witnessing moderate growth, with increasing investments in healthcare infrastructure and genomic research driving adoption.
Recent Developments
In February 2025, Illumina launched a new next-generation sequencing platform aimed at enhancing the accuracy and efficiency of precision genomic testing. In December 2024, the US FDA approved a novel liquid biopsy test for early cancer detection, paving the way for wider adoption of precision genomic analysis in oncology. In October 2024, Qiagen announced a collaboration with AstraZeneca to develop companion diagnostics for targeted oncology treatments. In August 2024, Roche acquired Stratos Genomics to strengthen its position in the precision genomic testing market and expand its portfolio of diagnostic solutions. In June 2024, Thermo Fisher Scientific partnered with Genomics England to enhance genome sequencing capabilities for precision medicine research, highlighting the growing focus on advancing genomic testing technologies.
Precision Genomic Testing Market Companies
- Danaher
- Merck KGaA
- Revvity, Inc.
- Maravai LifeSciences
- GenScript
- QIAGEN
- PacBio
- Oxford Nanopore Technologies plc.
- Illumina, Inc.
- 10x Genomics, Inc.
Segments Covered in the Report
By Product & Service
- Consumables
- Kits
- Reagents
- Equipment
- Services
By Technology
- Next-Generation Sequencing
- Polymerase Chain Reaction
- Microarray Technology
- Sanger Sequencing
- CRISPR/Cas Systems
- Others
By Application
- Oncology
- Cardiovascular Diseases
- Neurological Disorders
- Reproductive Health
- Rare Diseases
- Others
By End Use
- Hospitals and Clinics
- Diagnostic Laboratories
- Research and Academic Institutes
- Others
By Geography
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Ready for more? Dive into the full experience on our website!
https://www.precedenceresearch.com/
